文献速递肝病消化道肿瘤与早癌

美国肝硬化患者基于风险的肝细胞癌监测:医疗服务提供者的态度调查

Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-09-12

该研究通过基于网络的调查,评估了美国17个州26个医疗中心的消化科和肝病科提供者对肝硬化患者肝细胞癌监测的看法。共305名提供者完成调查,98.4%支持半年一次监测,多数推荐超声±甲胎蛋白;随着患者肝细胞癌年风险从1%升至3%至5%,提供者更少选择超声±甲胎蛋白(83.6%至68.9%至57.4%;P < .001),更多选择CT或MRI±甲胎蛋白(3.9%至26.2%至36.1%;P < .001)。

要点

  • 98.4%的提供者支持肝硬化患者每半年一次肝细胞癌监测。
  • 84.2%推荐超声±甲胎蛋白,15.4%推荐CT或MRI。
  • 患者肝细胞癌年风险从1%升至5%时,提供者选择超声±甲胎蛋白的比例下降,选择CT或MRI±甲胎蛋白的比例上升。

核心结论

  • 提供者推荐肝细胞癌监测的阈值远低于专业学会建议的阈值。
  • 许多提供者对基于患者估计肝细胞癌风险的监测策略持接受态度,而非当前「一刀切」策略。

研究设计与样本

  • 基于网络的调查,对象为来自美国17个州26个医疗中心的消化科和肝病科提供者(40%为教师医师,21%为高级实践提供者,39%为专科培训学员)。
  • 654名符合条件的提供者中,305名(47%)完成了调查。

主要发现

  • 98.4%的提供者支持肝硬化患者每半年一次肝细胞癌监测。
  • 84.2%推荐超声±甲胎蛋白,15.4%推荐CT或MRI。
  • 监测障碍包括肝细胞癌治疗选择有限、筛查试验降低死亡率的效果、交通可及性和高自付费用。
  • 监测促进因素包括专业学会指南。
  • 72.1%的提供者即使肝细胞癌年风险低(≤0.5%)也会进行监测,98.7%在年风险≥1%时会进行监测。

关键数值与推荐

  • 98.4%的提供者支持肝硬化患者每半年一次肝细胞癌监测。
  • 84.2%的提供者推荐超声±甲胎蛋白作为监测方式。
  • 15.4%的提供者推荐CT或MRI作为监测方式。
  • 72.1%的提供者在肝细胞癌年风险≤0.5%时仍会进行监测;98.7%在年风险≥1%时会进行监测。
  • 患者肝细胞癌年风险从1%升至3%至5%时,推荐超声±甲胎蛋白的比例从83.6%降至68.9%再降至57.4%(P < .001),推荐CT或MRI±甲胎蛋白的比例从3.9%升至26.2%再升至36.1%(P < .001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) surveillance rates are suboptimal in clinical practice. We aimed to elicit providers' opinions on the following aspects of HCC surveillance: preferred strategies, barriers and facilitators, and the impact of a patient's HCC risk on the choice of surveillance modality. METHODS: We conducted a web-based survey among gastroenterology and hepatology providers (40% faculty physicians, 21% advanced practice providers, 39% fellow-trainees) from 26 US medical centers in 17 states. RESULTS: Of 654 eligible providers, 305 (47%) completed the survey. Nearly all (98.4%) of the providers endorsed semi-annual HCC surveillance in patients with cirrhosis, with 84.2% recommending ultrasound ± alpha fetoprotein (AFP) and 15.4% recommending computed tomography (CT) or magnetic resonance imaging (MRI). Barriers to surveillance included limited HCC treatment options, screening test effectiveness to reduce mortality, access to transportation, and high out-of-pocket costs. Facilitators of surveillance included professional society guidelines. Most providers (72.1%) would perform surveillance even if HCC risk was low (≤0.5% per year), while 98.7% would perform surveillance if HCC risk was ≥1% per year. As a patient's HCC risk increased from 1% to 3% to 5% per year, providers reported they would be less likely to order ultrasound ± AFP (83.6% to 68.9% to 57.4%; P < .001) and more likely to order CT or MRI ± AFP (3.9% to 26.2% to 36.1%; P < .001). CONCLUSIONS: Providers recommend HCC surveillance even when HCC risk is much lower than the threshold suggested by professional societies. Many appear receptive to risk-based HCC surveillance strategies that depend on patients' estimated HCC risk, instead of our current "one-size-fits all" strategy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, et al. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clin Gastroenterol Hepatol. 2020. PMID: 32927050. doi:10.1016/j.cgh.2020.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。